Venture Capital Tracker is a free research layer for startup funding, venture capital firms, investor discovery, and source-backed market coverage.

Coverage snapshot

Know what’s in the dataset.

A growing research layer across funds, companies, and source-backed venture coverage.

862

VC firms

Profiles with stage, focus, and contact links.

2,186

Startups

Companies appearing in our funding coverage.

6

Latest signals

Fund closes and rounds in the investment feed.

1,492

Research articles

Analysis, explainers, and market roundups.

Deal flow

Latest funding & fund-close signals

A date-first view of the newest entries in the Venture Capital Tracker feed. Open each item for the full context and source trail.

View full feed
Funding round Nov 16

Stark Future closes financing with more than €150M total transaction value at €1.2B pre-money valuation

Issuer and participating investor on Nov 16 confirmed a CLOSED financing transaction with MORE THAN €150M in TOTAL transaction value, led by Highland Europe with Morgan Stanley 1GT and Axon. Company reports €1.2B PRE-money valuation. Breakdown between fresh primary company cash and potential secondary or other deal components was NOT disclosed. A possible second closing remains uncompleted. Product is a commercial VARG electric motorcycle range, not a preclinical concept. €150M is a strict lower bound on deal value, not precise cash raised.

Funding round Nov 16

Seawolf Therapeutics discloses $100M total across Seed and Series A, announces separate Sanofi pact

Seawolf publicly emerged November 16, 2026, disclosing $100M cumulatively raised in a Versant-led seed followed by a Series A involving Versant, MPM BioImpact, Novartis Venture Fund and others. Individual seed/A amounts and legal closing days are undisclosed; this is ONE combined historical disclosure, not a $100M Series A. A distinct Sanofi research/license arrangement includes up to $1.2B conditional milestones and royalties, NOT $1.2B startup financing, initial cash or company valuation. TRIDENT DNA-LNP clinical results remain preclinical.

Funding round Nov 16

Corma raises $125M Series A led by NEA at reported $1B valuation

Issuer-announced November 16, 2026 Series A of $125M led by New Enterprise Associates; existing investors Sequoia, Khosla Ventures and Coatue participated. The company reports $185M cumulative disclosed equity funding after its separate August $60M seed. The $1B valuation's pre/post-money basis and precise closing day are not specified; company claims about autonomous security outcomes are unverified commercial metrics.

Acquisition Nov 16

Johnson & Johnson agrees to acquire Ollin for $2.2B upfront plus up to $1.125B milestones

Nov 16 definitive acquisition agreement, not yet legally closed. $2.2B cash upfront plus up to approximately $1.125B in future regulatory and commercial payments; maximum contingent transaction consideration about $3.325B. Separately Blackstone will fund $750M toward J&J's Phase 3 program across multiple years for milestones and royalties. That development funding is NOT acquisition consideration or new Ollin equity. OLN324 investigational; close targeted before end of 2026.

Acquisition Nov 16

Lilly agrees to buy Calytrix Bio for up to $1.5B including contingent clinical milestones

Definitive agreement announced November 16, not completed acquisition. Maximum possible $1.5B cash to Calytrix shareholders comprises undisclosed upfront consideration and additional clinical/regulatory milestone payments. Actual upfront, certainty of milestones, and legal close date undisclosed. Calytrix remains private pending confirmed close.

Funding round Nov 16

Remedy Robotics announces $62M Series B led by DCVC for investigational N1 system

Company-disclosed $62M Series B for pivotal clinical study preparation, FDA regulatory pathway and N1 prototypes. DCVC leads; UC Investments, Skip Capital, Hostplus and existing backers participate. N1 is investigational, not commercially available or approved. Legal financing closing date and valuation undisclosed.

Go deeper

Research the market your way.

Use the structured pages when you need a shortlist, a company read, or a plain-English answer about how venture capital works.

Built from structured profiles and source-backed editorial coverage. How we curate the data